Clinical trial

Trial for Local Ablative Treatment (LAT) Optimization in Patients With Advanced Non-Small Cells Lung Cancer (NSCLC) Presenting an Anaplastic Lymphoma Kinase (ALK) Rearrangement Treated by Brigatinib

NCT06620835

Study summary

ClinicalTrials.gov

Trial for Local Ablative Treatment (LAT) Optimization in Patients With Advanced Non-Small Cells Lung Cancer (NSCLC) Presenting an Anaplastic Lymphoma Kinase (ALK) Rearrangement Treated by Brigatinib

Design: INTERVENTIONAL · Status: RECRUITING · Phase: PHASE2

Loading study purpose, treatment groups and outcomes…

View the complete registry record, eligibility and contacts at ClinicalTrials.gov

Drugs and interventions used in this trial

6 registered

These interventions are listed by ClinicalTrials.gov. An RxNorm link indicates a mapped medicine record; the registry name alone is not proof of a specific branded formulation.

BIOLOGICAL · Unmapped registry intervention Blood samples for Hematology Find medicine records · Find other trials using this name

BIOLOGICAL · Unmapped registry intervention Blood samples for Chemistry Find medicine records · Find other trials using this name

BIOLOGICAL · Unmapped registry intervention Blood sample for liver function tests Find medicine records · Find other trials using this name

BIOLOGICAL · Unmapped registry intervention Pregnancy test Find medicine records · Find other trials using this name

PROCEDURE · Unmapped registry intervention Tumour assessment Find medicine records · Find other trials using this name

PROCEDURE · Unmapped registry intervention Local Ablative Therapy (LAT) Find medicine records · Find other trials using this name

StatusRECRUITING

Study typeINTERVENTIONAL

Start date2025-06-19

PhasePHASE2

Conditions

NSCLCverified · MONDO: non-small cell lung carcinoma

Interventions

Blood samples for HematologyBIOLOGICAL

Blood samples for ChemistryBIOLOGICAL

Blood sample for liver function testsBIOLOGICAL

Pregnancy testBIOLOGICAL

Tumour assessmentPROCEDURE

Local Ablative Therapy (LAT)PROCEDURE

Sponsors & collaborators

Groupe Francais De Pneumo-Cancerologielead sponsor

Mapped research locations

RennesFrance2 ParisFrance1 MarseilleFrance1 LyonFrance1 StrasbourgFrance1 NiceFrance1 DijonFrance1 CaenFrance1 RouenFrance1 BrestFrance1 CréteilFrance1 NîmesFrance1

Registry source

Open the source record to verify current eligibility, contacts, locations and registry updates.

Open NCT06620835 on ClinicalTrials.gov ↗

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.